卡非佐米与硼替佐米治疗伴肾功能衰竭的多发性骨髓瘤患者:ENDEAVOR研究亚组分析
ENDEAVOR研究的事后探索性亚组分析按基线肾功能分层,比较卡非佐米(56 mg/m2)联合地塞米松(Kd56)与硼替佐米联合地塞米松(Vd)在复发/难治多发性骨髓瘤中的疗效。结果显示,无论基线肾功能如何,Kd56相较Vd均改善无进展生存期和总生存期。
要点
- 在肌酐清除率≥15至<50 mL/min亚组,Kd56组中位PFS为14.9个月,Vd组为6.5个月(HR 0.49)。
- 在肌酐清除率≥15至<50 mL/min亚组,Kd56组中位OS为42.1个月,Vd组为23.7个月(HR 0.66)。
- 合并Kd56与Vd分析中,肾脏完全缓解者较未缓解者中位PFS为14.1 vs 9.4个月(HR 0.805)。
核心结论
- 在复发/难治多发性骨髓瘤患者中,无论基线肾功能如何,Kd56相较Vd均显示无进展生存期和总生存期改善。
研究设计与样本
- ENDEAVOR研究的事后探索性亚组分析,按基线肾功能分层比较Kd56与Vd。
- 意向治疗人群共929例,肌酐清除率≥15至<50 mL/min者Kd56组85例、Vd组99例;50至<80 mL/min者Kd56组186例、Vd组177例;≥80 mL/min者Kd56组193例、Vd组189例。
主要发现
- 肌酐清除率≥15至<50 mL/min亚组中位PFS为Kd56组14.9个月 vs Vd组6.5个月(HR 0.49;95%CI 0.320-0.757),中位OS为Kd56组42.1个月 vs Vd组23.7个月(HR 0.66;95%CI 0.443-0.989)。
- 肌酐清除率50至<80 mL/min亚组中位PFS为Kd56组18.6个月 vs Vd组9.4个月(HR 0.48;95%CI 0.351-0.652),中位OS为Kd56组42.5个月 vs Vd组32.8个月(HR 0.83;95%CI 0.626-1.104)。
- 肌酐清除率≥80 mL/min亚组中位PFS为Kd56组未达到 vs Vd组12.2个月(HR 0.60;95%CI 0.434-0.827),中位OS为Kd56组未达到 vs Vd组42.3个月(HR 0.75;95%CI 0.554-1.009)。
- 肾脏完全缓解率(基线肌酐清除率<50 mL/min者连续两次访视肌酐清除率改善至≥60 mL/min)为Kd56组15.3%(95%CI 8.4-24.7)vs Vd组14.1%(95%CI 8.0-22.6)。
- 合并Kd56与Vd分析中,肾脏完全缓解者较未缓解者中位PFS为14.1 vs 9.4个月(HR 0.805;95%CI 0.438-1.481),中位OS为35.3 vs 29.7个月(HR 0.91;95%CI 0.524-1.577)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In ENDEAVOR, carfilzomib (56 mg/m2) and dexamethasone (Kd56) demonstrated longer progression-free survival (PFS) over bortezomib and dexamethasone (Vd) in patients with relapsed/refractory multiple myeloma (RRMM). Here we evaluated Kd56 vs Vd by baseline renal function in a post hoc exploratory subgroup analysis. The intent-to-treat population included 929 patients (creatinine clearance [CrCL] ≥15 to <50 mL/min, n = 85 and n = 99; CrCL 50 to <80 mL/min, n = 186 and n = 177; and CrCL ≥80 mL/min, n = 193 and n = 189 for Kd56 and Vd arms, respectively). In these respective subgroups, median PFS was 14.9 vs 6.5 months (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.320-0.757), 18.6 vs 9.4 months (HR, 0.48; 95% CI, 0.351-0.652), and not reached (NR) vs 12.2 months (HR, 0.60; 95% CI, 0.434-0.827) for those receiving Kd56 vs Vd, respectively; median overall survival (OS) was 42.1 vs 23.7 months (HR, 0.66; 95% CI, 0.443-0.989), 42.5 vs 32.8 months (HR, 0.83; 95% CI, 0.626-1.104), and NR vs 42.3 months (HR, 0.75; 95% CI, 0.554-1.009). Complete renal response (ie, CrCL improvement to ≥60 mL/min in any 2 consecutive visits if baseline CrCL <50 mL/min) rates were 15.3% (95% CI, 8.4-24.7) and 14.1% (95% CI, 8.0-22.6) for those receiving Kd56 vs Vd, respectively. In a combined Kd56 and Vd analysis, complete renal responders had longer median PFS (14.1 vs 9.4 months; HR, 0.805; 95% CI, 0.438-1.481) and OS (35.3 vs 29.7 months; HR, 0.91; 95% CI, 0.524-1.577) vs nonresponders. Grade ≥3 adverse event rates in the respective subgroups were 87.1% vs 79.4%, 84.4% vs 71.8%, and 77.1% vs 65.9% for those receiving Kd56 vs Vd, respectively. Thus, Kd56 demonstrated PFS and OS improvements over Vd in RRMM patients regardless of their baseline renal function. The ENDEAVOR trial was registered at www.clinicaltrials.gov as #NCT01568866.
引用
- Dimopoulos M, Siegel D, White DJ, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood. 2018. PMID: 30478094. doi:10.1182/blood-2018-06-860015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。